Show simple item record

dc.contributor.authorBerry, A.A.
dc.contributor.authorAbu-Elyazeed, R.
dc.contributor.authorDiaz-Perez, C.
dc.date.accessioned2019-07-15T16:16:56Z
dc.date.available2019-07-15T16:16:56Z
dc.date.issued2017
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85019589141&doi=10.1080%2f21645515.2017.1309486&partnerID=40&md5=e9397cfa58ab64db2c2370eb597593c2
dc.identifier.urihttp://hdl.handle.net/10713/9999
dc.description.abstractOne combined measles-mumps-rubella (MMR) vaccine without Human Serum Albumin (HSA) is currently licensed in the USA (M-M-R II; Merck, USA) and another has been developed (Priorix™ [MMR-RIT, GSK, Belgium]). In this follow-up study, children from USA or Puerto Rico, who had received one dose of M-M-R II or MMR-RIT at 12–15 months of age in the primary study (NCT00861744), were followed-up for 2 y post-vaccination. Anti-measles and anti-rubella antibodies were measured using Enzyme-Linked Immunosorbent Assay (ELISA), and anti-mumps antibodies using ELISA and plaque reduction neutralization (PRN) assays. Serious adverse events (SAEs) were recorded during the entire follow-up. The according-to-protocol (ATP) persistence cohort included 752 children (M-M-R II = 186, MMR-RIT = 566), who received primary vaccination at a mean age of 12.3 ( ± 0.67) months. 104 children were revaccinated with MMR-containing vaccines; therefore, serology results for timepoints after revaccination were excluded from the analysis. Seropositivity for measles (Year 1≥ 98.3%; Year 2≥ 99.4%) and rubella (Year 1≥ 98.9%; Year 2 = 100%) remained as high at Year 2 as at Day 42. Similarly, seropositivity for mumps determined by ELISA (Year 1≥ 90.1%; Year 2≥ 94.1%) and PRN assays (Year 1≥ 87.5%; Year 2≥ 91.7%) persisted. Thirty-three SAEs were recorded in 23 children; 2 SAEs (inguinal adenitis and idiopathic thrombocytopenic purpura) and one SAE (febrile convulsion) were considered as potentially related to MMR-RIT and M-M-R II, respectively. This study showed that antibodies against measles, mumps and rubella persisted for up to 2 y post-vaccination with either MMR vaccine in children aged 12–15 months, and that both vaccines were well-tolerated during the follow-up period. Copyright 2017 The Author(s). Published with license by Taylor & Francis Copyright 2017, Copyright Andrea A. Berry, Remon Abu-Elyazeed, Clemente Diaz-Perez, Maurice A. Mufson, Christopher J. Harrison, Michael Leonardi, Jerry D. Twiggs, Christopher Peltier, Stanley Grogg, Antonio Carbayo, Steven Shapiro, Michael Povey, Carmen Baccarini, Bruce L. Innis, and Ouzama Henry.en_US
dc.description.urihttps://www.doi.org/10.1080/21645515.2017.1309486en_US
dc.language.isoen_USen_US
dc.publisherTaylor and Francis Inc.en_US
dc.relation.ispartofHuman Vaccines and Immunotherapeutics
dc.subjectantibody persistenceen_US
dc.subjectmeaslesen_US
dc.subjectMMR vaccineen_US
dc.subjectmumpsen_US
dc.subjectPriorixen_US
dc.subjectrubellaen_US
dc.titleTwo-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albuminen_US
dc.typeArticleen_US
dc.identifier.doi10.1080/21645515.2017.1309486
dc.identifier.pmid28481690


This item appears in the following Collection(s)

Show simple item record